



Original contribution

Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer

Masakazu Fujimoto MD^a, Akihiko Yoshizawa MD^{a,b}, Shinji Sumiyoshi MD^a,
Makoto Sonobe MD^c, Masashi Kobayashi MD^c, Itsuko Koyanagi^a,
Wulamujiang Aini PhD^a, Tatsuaki Tsuruyama MD^a, Hiroshi Date MD^c, Hironori Haga MD^{a,*}

^aDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto 606-8507, Japan

^bDepartment of Laboratory Medicine, Shinshu University Hospital, Matsumoto 390-8621, Japan

^cDepartment of Thoracic Surgery, Kyoto University Hospital, Kyoto 606-8507, Japan

Received 3 October 2012; revised 21 December 2012; accepted 3 January 2013

Keywords:

IgG4;
Plasma cell;
Lung carcinoma;
Tissue microarray

Summary Inflammatory cell infiltration in tumor stroma may represent the interaction between the tumor and the immune system. The significance of immunoglobulin (Ig) G4+ plasmacytic infiltration, however, is poorly understood. Here, we analyzed the number of stromal IgG4+ plasma cells and the IgG4/IgG ratio of plasma cells in 294 primary non-small cell lung cancers (NSCLCs) using tissue microarray (TMA) and conventional surgical specimens. In TMA, 35 (12%) cases of NSCLC revealed more than 20 IgG4+ plasma cells per high-power field. In surgical specimens, most (97%) of those IgG4+ plasma cell-enriched cases showed obliterative phlebitis or arteritis, one of the key morphologic features of IgG4-related disease, within or at the periphery of the tumor. Clinically, none of the patients showed symptoms associated with IgG4-related systemic diseases. In patients with stage I squamous cell carcinoma, IgG4-enriched stroma was significantly associated with a favorable prognosis ($P = .04$). In conclusion, considerable IgG4+ plasma cell infiltration can be seen in a minority of cases of NSCLC and might contribute to prognostic modulation of NSCLC.

© 2013 Elsevier Inc. All rights reserved.

1. Introduction

Despite a number of recent studies focused on the tumor microenvironment, the role of plasma cells in cancer is not well understood [1]. The class and subclass of immunoglobulin (Ig) produced by plasma cells are defined primarily by their heavy-chain constant domain sequences, which affect the function of the antibody [2]. IgG4, the least abundant

subclass in the IgG class, shows weak or negligible binding ability to both C1q and Fcγ receptors compared with the other IgG subclasses, which leads to a limited capacity to activate the classical complement pathway [2,3]. Thus, until recently, it was believed that IgG4 plays only a limited role in immune activation [3]. As a consequence of the current familiarity of IgG4-related diseases (IgG4-RD) to pathologists and the widespread use of anti-IgG4 antibody for immunohistochemical staining, cases of carcinoma accompanied by severe IgG4+ plasma cell infiltration in patients with or without a medical history of IgG4-RD have been identified [4–9], although the prevalence and significance of this phenomenon remain unclear.

* Corresponding author. Department of Diagnostic Pathology, Kyoto University Hospital, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.

E-mail address: haga@kuhp.kyoto-u.ac.jp (H. Haga).

Table 1 Comparison of lung cancers with and without greater than 20 IgG4+ plasma cells/HPF in the TMA core (n = 294)

	No. of IgG4+ plasma cells/TMA core		<i>P</i>
	>20/HPF	≤20/HPF	
No. of cases	35 (11.9%)	259 (88.1%)	
IgG4/IgG ratio in TMA core, median (range)	0.13 (0.021-0.47)	0 (0-0.75)	<.0001 *
Male	30 (85.7%)	144 (55.6%)	.0005 *
Age (y), median (range)	72 (41-88)	67 (23-94)	.1783
Never smokers	4 (11.4%)	107 (41.3%)	.0004 *
Preoperative history of cancer	7 (20.0%)	48 (18.5%)	.8189
Preoperative history of asthma	4 (11.4%)	8 (3.1%)	.0417 *
Preoperative history of collagen vascular disease	1 (2.8%)	9 (3.5%)	1
Preoperative history of interstitial pneumonia	1 (2.9%)	15 (5.8%)	.7032
Squamous cell carcinomas (G1/G2/G3)	17 (3/12/2) (48.6%)	35 (6/18/11) (13.5%)	<.0001 *
G3 squamous cell carcinomas	2 (5.7%)	11 (4.2%)	.6583
Adenocarcinomas (G1/G2/G3)	17 (0/2/15) (48.6%)	216 (60/88/68) (83.4%)	.0001 *
G3 adenocarcinomas	15 (42.9%)	68 (26.3%)	.0468 *
Gene mutation in adenocarcinomas			
<i>EGFR</i>	3/14 (21.4%)	99/199 (49.0%)	.0524
<i>KRAS</i>	1/14 (7.1%)	22/199 (11.1%)	1
<i>TP53</i>	5/7 (71.4%)	26/122 (21.3%)	.0088 *
Stage I cancers	19 (54.3%)	196 (75.7%)	.0134 *
Recurrence rate ^a	34.3% (10.5%)	32.8% (20.9%)	.8502 (.3773)
Death rate ^a	20.0% (0%)	22.8% (12.2%)	.8111 (.1395)

^a Of stage I cancers.

* Statistically significant.

Differential diagnosis of IgG4-RD and cancers can be problematic because IgG4-RD often forms tumefactive lesions and peritumoral desmoplastic tissue can mimic IgG4-RD when there is an abundance of IgG4+ plasma cells in a biopsy specimen. Some morphologic findings such as obliterative phlebitis are considered to be rather more specific to IgG4-RD than to cancer, but existing evidence

supporting this idea seems weak [10]. Serum IgG4 concentration is a helpful laboratory finding to differentiate IgG4-RD and cancer, but it is not always elevated in patients with IgG4-RD, whereas it can be elevated in patients with cancer without IgG4-RD [4,8]. In addition, clinicians must keep in mind the possibility of synchronous cancer and IgG4-RD [11].

Table 2 Logistic regression analysis for estimation of significant factors related to greater than 20/HPF intratumoral IgG4+ plasma cell infiltration

Variable	Odds ratio	95% CI	<i>P</i>
Sex (male/female)	1.8285	0.5631-6.9714	.3392
Smoking history (never/current or former)	0.6118	0.1400-2.2837	.4829
Preoperative history of asthma (present/absent)	2.7665	0.6253-11.2757	.1581
Squamous cell carcinoma	15.4307	4.5863-71.6024	<.0001 *
G3 adenocarcinoma	8.5662	2.5946-38.8643	.0013 *
Cancer stage (stage I/stage II-IV)	0.6655	0.2968-1.4987	.3215

* Statistically significant.

In this study, we identified cases of lung cancer with stromal IgG4+ plasma cell infiltration using tissue microarray (TMA). We analyzed the clinicopathologic characteristics of these cases to investigate the relevance of lung cancer and IgG4+ plasma cells.

2. Materials and methods

2.1. Tissue microarray

Paraffin-embedded tumor blocks from 363 cases of lung cancer surgically resected from different patients in Kyoto University Hospital between 2001 and 2007 were selected from the electronic pathology files of Kyoto University Hospital for construction of TMA, with the patients' consent. TMAs were constructed by 2 of the authors (A.Y. and S.S.) basically using the approach described by Kononen et al [12]. Briefly, the most morphologically representative region of the tumor was selected on a hematoxylin and eosin-stained slide. Then, a tissue core 2 mm in diameter was punched out from each donor tumor block using a thin-walled stainless steel needle for TMA construction (Azumaya, Tokyo, Japan) and was arrayed in a recipient paraffin block. Small cell carcinomas, recurrent carcinomas, carcinomas with neoadjuvant chemotherapy, and cases with multiple carcinomas (both synchronous and metachronous), which were in the TMA for other research, were excluded from this study ($n = 45$).

2.2. Immunohistochemistry

Immunostains against IgG4 and IgG using mouse antihuman IgG4/HRP (MCA2098P, dilution 1:200; AbD Serotec, Oxford, UK) and IgG (polyclonal, dilution 1:2 of prediluted product; Ventana, Tucson, AZ) were performed on an autoimmunostainer (Ventana XT System Benchmark; Ventana Medical Systems).

2.3. Evaluation of immunohistochemistry

In TMA sections, we regarded tumors infiltrated by more than 20 IgG4+ plasma cells per high-power field (HPF) ($\times 40$ objective lens with field number 22) as IgG4+ cell-enriched cases because this criterion is used for diagnosing IgG4-RD in lung biopsy specimens [10]. To calculate the IgG4/IgG ratio in each TMA section, the total numbers of IgG4+ and IgG+ plasma cells per core were counted manually under a light microscope by M.F. and A.Y. For those IgG4+ cell-enriched cases with greater than 25% IgG4/IgG ratio, immunohistochemistry for IgG4 and IgG was performed on the original surgical specimens to extract the cases fulfilling the quantitative criteria for IgG4-RD (>50 /HPF of plasma cells with IgG4/IgG ratio $>40\%$) [10]. In each case, IgG4 and IgG were counted in

the region most highly stained for IgG4 in 3 HPFs to calculate the IgG4/IgG ratio.

2.4. Histologic evaluation

Histologic types of lung cancers were determined according to the 2004 World Health Organization classification [13]. In adenocarcinomas, the predominant histologic subtype or variant in each case was identified according to the new lung adenocarcinoma classification proposed by the International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society [14]. Non-small cell carcinomas were graded as well differentiated (G1), moderately differentiated (G2), and poorly differentiated (G3) based on the 2004 World Health Organization classification by 3 of the authors (M.F., A.Y., and S.S.) [13]. IgG4+ cell-enriched cases were evaluated by 2 of the authors (M.F. and A.Y.) for the presence of obliterative phlebitis/arteritis and increased number of eosinophils, which we defined as more than 50 eosinophils per 10 HPFs [6].

2.5. Clinical information

The electronic chart of Kyoto University Hospital, the electronic database of the Department of Thoracic




Fig. 1 Kaplan-Meier survival curves of 35 patients with stage I squamous cell carcinomas separated by the number of IgG4+ plasma cells/HPF in the TMA core (>20 /HPF versus ≤ 20 /HPF). A, OS curves (log-rank test, $P = .0409$). B, DFS curves (log-rank test, $P = .1053$).

Table 3 Clinicopathologic characteristics of 6 lung cancers that fulfilled the histologic criteria of lung IgG4-RD^a

	Case no.					
	1	2	3	4	5	6
Sex	Male	Male	Male	Male	Male	Male
Age at surgery (y)	59	61	61	65	72	75
Smoking status	Current	Former	Former	Former	Never	Current
Medical history	None	Hypopharyngeal squamous cell carcinoma	None	Asthma, hepatitis C	Diabetes mellitus, arrhythmia	Colon carcinoma, renal carcinoma (histology not available)
Site	Right upper lobe	Left upper lobe	Right lower lobe	Right upper lobe	Left upper lobe	Left lower lobe
Stage	1B (T2aN0M0)	1A (T1aN0M0)	1A (T1bN0M0)	1B (T2aN0M0)	2A (T1bN1M0)	1A (T1aN0M0)
Histology	Adenosquamous carcinoma, G3	Adenocarcinoma, solid predominant, G3	Squamous cell carcinoma, G1	Squamous cell carcinoma, G2	Adenocarcinoma, micropapillary predominant, G3	Squamous cell carcinoma, G2
Obliterative phlebitis/arteritis	Present	Present	Absent	Present	Present	Present
Eosinophilic infiltration >50/10 HPF	Absent	Absent	Absent	Present	Absent	Absent
IgG4/IgG ratio in TMA core (%)	206/820 (25.1)	570/1204 (47.3)	172/625 (27.5)	258/1012 (25.5)	216/648 (33.3)	348/1211 (28.7)
IgG4/IgG ratio in surgical specimen (%)	51.7/103.7 (49.9)	80.0/137.0 (58.4)	67.7/146.7 (46.1)	53.3/125.3 (42.5)	69.7/170.7 (40.8)	50.6/105.3 (48.1)
<i>EGFR</i>	Not done	Wild	Wild	Wild	Mutated	Wild
<i>KRAS</i>	Not done	Mutated	Wild	Wild	Wild	Wild
<i>TP53</i>	Not done	Not done	Mutated	Wild	Not done	Wild
Recurrence of lung carcinoma	Absent	Absent	Absent	Absent	Present	Absent
Outcome	Alive	Alive	Alive	Alive	Died of disease	Alive
Follow-up period (days)	3480	1666	2747	2002	376	1468

^a IgG4/IgG ratio >40% and >50/HPF IgG4+ plasma cells in surgical specimen.

Surgery of Kyoto University Hospital, and the electronic pathology database of Kyoto University Hospital were used to search for patients' prognosis and medical history.


2.6. Somatic *EGFR*, *KRAS*, and *TP53* mutations

EGFR, *KRAS*, and *TP53* mutation analyses were performed in selected cases by methods described previously [15,16].

2.7. Statistical analysis

GraphPad Prism (GraphPad Software, San Diego, CA) and JMP Start Statistics (Statistical Discovery Software SAS Institute, Cary, NC) were used for statistical analyses. Comparisons between 2 groups were performed using the Fisher exact test or Mann-Whitney test to analyze categorical variables and continuous variables, respectively. The Kaplan-Meier method was used to evaluate patients' prognosis,

Fig. 2 Histology of lung cancers fulfilling the histologic criteria for lung IgG4-RD, A-E, Case 2. F-H, Case 4. A, Case 2, solid predominant G3 adenocarcinoma (×20). B, Higher-magnification image of boxed area in panel A (×100). C, Intratumoral obliterative phlebitis (×100). D, IgG4+ plasma cells of greater than 50/HPF in the cancer stroma (×200). E, IgG immunostain at the same area as in panel D, with IgG4/IgG ratio greater than 40% (×200). F, Case 4, squamous cell carcinoma, G2 (×40). G and H, Higher magnification of the areas demarcated by boxes in panel F; obliterative vasculitis and eosinophilic infiltration are shown, respectively (×200 and ×400).



and log-rank tests were used to compare the survival rates among groups. Logistic regression analysis was performed to examine the interaction of the multiple clinicopathologic variables. Significance was defined as $P < .05$.

3. Results

TMA cores that were not completely enclosed on the sections or did not include viable tumor on the sections were excluded from this study ($n = 24$). As a result, 294 primary non-small cell lung carcinomas (NSCLCs) were extracted. The median follow-up period of patients was 1748 days (range, 7-3805).

The 294 lung cancers consisted of 233 adenocarcinomas (79.3%), 52 squamous cell carcinomas (17.7%), and 9 other NSCLC (3.1%) (6 large cell carcinomas, 2 sarcomatoid carcinomas, and 1 adenosquamous carcinoma). According to the 7th Union for International Cancer Control (UICC) TNM classification [17], 215 cases (73.1%) were stage I, 37 cases (12.6%) were stage II, 31 cases (10.5%) were stage III, and 11 cases (3.7%) were stage IV. Among the 233 adenocarcinomas, 60 cases (25.8%) were G1, 90 cases (38.6%) were G2, and 83 cases (35.6%) were G3. Among the 52 squamous cell carcinomas, 9 cases (17.3%) were G1, 30 cases (57.7%) were G2, and 13 cases (25.0%) were G3. The median numbers of IgG4+ and IgG+ plasma cells in the TMA core were 0 (range, 0-570) and 134 (range, 0-2178), respectively. None of the 294 patients had IgG4-RD in their medical history, and serum IgG4 concentration was not measured in any of the patients.

In adenocarcinomas, mutation analysis of *EGFR*, *KRAS*, and *TP53* was performed in 213, 213, and 129 cases, respectively, and the mutation was confirmed in 102 (47.9%), 23 (10.8%), and 31 cases (24.0%), respectively.

3.1. Lung cancers with IgG4+ cell enrichment ($n = 35$)

Of 294 cases, 35 cases (11.9%) were IgG4+ cell-enriched, including 17 adenocarcinomas (7.3% of all adenocarcinomas), 17 squamous cell carcinomas (32.7% of all squamous cell carcinomas), and 1 adenosquamous carcinoma. Among the 17 adenocarcinomas, 15 cases (88.2%) were G3 and 2 cases (11.8%) were G2. G1 adenocarcinoma was not observed. Among the 17 squamous cell carcinomas, 3 cases (17.6%) were G1, 12 cases (70.6%) were G2, and 2 cases (11.8%) were G3.

The median number of original tumor slides observed per case was 3 (range, 1-9), and Victoria blue hematoxylin and eosin stain and/or Elastica van Gieson stain was performed in all but 1 case. Fibrosis was evident in cancer stroma of all 35 cases, but none of them showed storiform pattern fibrosis. Obliterative phlebitis/arteritis was found in 34 cases (97.1%) associated with desmoplasia. An increased number of eosinophils were seen in 3 cases (8.6%). In all 35 cases, pathological change for which IgG4-RD was suspected was absent in nonneoplastic lung tissue surrounding the cancers.

The result of comparison between IgG4+ cell-enriched cases and the cases with at least 20 IgG4+/HPF in the TMA core is shown in Table 1. We also performed multivariate logistic regression analysis to determine which factors, among those showing statistical significance in univariate analysis, were more significantly associated with greater than 20/HPF IgG4+ plasma cell infiltration (Table 2). This analysis revealed that squamous cell carcinoma and G3 adenocarcinoma were associated with greater than 20/HPF IgG4+ plasma cell infiltration with high statistical significance ($P < .0001$ and $P = .0013$, respectively).

No statistical difference in recurrence rate or death rate was observed between the 2 groups (Table 1). In stage I carcinoma, however, none of the 19 IgG4+ cell-enriched cases (10 adenocarcinomas, 8 squamous cell carcinomas, and 1 adenosquamous carcinoma) were associated with patient death, and only 1 squamous cell carcinoma and 1 adenocarcinoma recurred. In contrast, among 27 stage I squamous cell carcinomas with at least 20 IgG4+ plasma cells/HPF, 10 patients (37.0%) died of disease and 11 cases (40.7%) recurred. Among 110 stage I G2-3 adenocarcinomas with at least 20 IgG4+ plasma cells/HPF, 13 patients (11.8%) died of disease and 29 cases (26.4%) recurred. A significant difference of overall survival (OS) rate was observed in stage I squamous cell carcinoma ($P = .0409$), but this was not the case for disease-free survival (DFS) rate ($P = .1053$; Fig. 1). No significant difference in OS or DFS was observed in stage I G2-3 adenocarcinoma ($P = .3280$ and $P = .4407$, respectively).

3.2. Lung cancers with greater than 50 IgG4+ plasma cells/HPF and greater than 40% IgG4/IgG plasma cells in surgical specimens ($n = 6$)

Among 35 IgG4+ cell-enriched cases in the TMA cores, 12 cases were associated with greater than 25% IgG4/IgG ratio, and 6 of them showed greater than 50 IgG4+ plasma cells/HPF and greater than 40% IgG4/IgG ratio in the surgical specimens. The clinicopathologic features of these 6 cases are summarized in Table 3. Histologic figures of selected cases are shown in Fig. 2.

In comparison of these 6 cases and the other 29 IgG4+ cell-enriched cases, no statistically significant difference was obtained in any parameters shown in Table 1, except the IgG4/IgG ratio in the TMA core (median, 0.28 versus 0.12; $P = .0062$). In addition, the numbers of cases with obliterative phlebitis/arteritis and increased number of eosinophils in these 2 groups did not differ significantly (83.3% versus 100% [$P = .1714$] and 16.7% versus 6.9% [$P = .4417$], respectively).

4. Discussion

IgG4+ plasma cell infiltration in cancer and its relevance to IgG4-RD have been a matter of debate in practical

medicine [4-9]. Because chronic inflammation is associated with a risk of cancer development, it could be hypothesized that IgG4-RD is a source of carcinoma [11,18]. In our series, however, the idea that the patients with IgG4+ cell-enriched tumor had lung IgG4-RD seems unlikely for 2 main reasons. Firstly, none of the IgG4+ cell-enriched cases showed histology of IgG4-RD in the nonneoplastic lung tissue, suggesting that the cancer is the factor causing the inflammation and not the other way round. Second, although IgG4-RD is a systemic disease and the affected patients commonly develop multivisceral lesions or multiple lesions in the same organ at the time of diagnosis or during the follow-up [6,19], none of the patients in our series were clinically complicated by IgG4-RD at the time of diagnosis or during the follow-up of cancer.

Considering the favorable prognosis observed in IgG4-enriched stage I squamous cell carcinomas, IgG4 infiltration might cause prognostic modulation of NSCLC. At first, this result seemed inconsistent with the notable antiimmune function of IgG4, as seen in the transition of serum IgG4 level in immunotherapy [20]. Other previous reports, however, show that the functional role of IgG4 varies in different pathophysiologic circumstances and that IgG4 can be a pathogenic antibody in certain immunologic disorders [21-25]. Our data may suggest that IgG4 reacts against certain lung cancer antigens and damages tumor cells despite its poor complement- and leucocyte-activating properties. By multivariate analysis, we found that squamous cell carcinomas and high-grade adenocarcinomas are more likely to be accompanied by intratumoral IgG4+ plasma cells; however, the reason for this tendency is unclear at present.

In stage I squamous cell carcinoma, intratumoral IgG4+ plasma cell infiltration may be a better prognostic factor than conventional histologic grade because the histologic grade of lung squamous cell carcinoma is not clearly related to its prognosis [13]. IgG4+ plasma cells might have a cancer-inhibiting role in adenocarcinomas as well, but our data did not show statistical significance. In adenocarcinomas, high-grade histology or non-*EGFR* gene mutation may be a more powerful prognostic factor than IgG4+ cell infiltration [15,16,26].

A common histologic finding of IgG4-RD is sclerosing fibrosis arranged at least focally in a storiform pattern accompanied by marked IgG4+ plasma cell infiltration, usually associated with obliterative phlebitis; however, there is variability in the findings in certain organs [10]. In lung IgG4-RD, storiform-type fibrosis is uncommon; thus, histologic findings tend to overlap with other pulmonary fibroinflammatory conditions. In the pericancerous fibrous stroma of our IgG4+ cell-enriched cancers, even obliterative phlebitis/arteritis, the histologic finding of which is believed to be quite specific to lung IgG4-RD, was observed in most cases. Pathologists should be aware of this fact when diagnosing lung IgG4-RD on biopsy specimens.

In conclusion, a nonnegligible minority of cases of squamous cell carcinoma and high-grade adenocarcinoma of

the lung showed IgG4+ plasma cell infiltration in the stroma. Obliterative vascular changes were commonly seen in those cases without clinical evidence of IgG4-RD. Because IgG4+ cell-enriched cases were associated with favorable prognosis in stage I squamous cell carcinomas, IgG4 infiltration may be part of the anticancer immune response.

References

- [1] Bremnes RM, Al-Shibli K, Donnem T, et al. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. *J Thorac Oncol* 2011; 6:824-33.
- [2] Nirula A, Glaser SM, Kalled SL, Taylor FR. What is IgG4? A review of the biology of a unique immunoglobulin subtype. *Curr Opin Rheumatol* 2011;23:119-24.
- [3] Stone JH, Zen Y, Deshpande V. IgG4-related disease. *N Engl J Med* 2012;366:539-51.
- [4] Ghazale A, Chari ST, Smyrk TC, et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. *Am J Gastroenterol* 2007;102:1646-53.
- [5] Witkiewicz AK, Kennedy EP, Kenyon L, Yeo CJ, Hruban RH. Synchronous autoimmune pancreatitis and infiltrating pancreatic ductal adenocarcinoma: case report and review of the literature. *HUM PATHOL* 2008;39:1548-51.
- [6] Zen Y, Inoue D, Kitao A, et al. IgG4-related lung and pleural disease: a clinicopathologic study of 21 cases. *Am J Surg Pathol* 2009;33: 1886-93.
- [7] Strehl JD, Hartmann A, Agaimy A. Numerous IgG4-positive plasma cells are ubiquitous in diverse localised non-specific chronic inflammatory conditions and need to be distinguished from IgG4-related systemic disorders. *J Clin Pathol* 2011;64:237-43.
- [8] Oseini AM, Chaiteerakij R, Shire AM, et al. Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. *Hepatology* 2011;54: 940-8.
- [9] Tian W, Yakirevich E, Matoso A, Gnepp DR. IgG4+ plasma cells in sclerosing variant of mucoepidermoid carcinoma. *Am J Surg Pathol* 2012;36:973-9.
- [10] Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. *Mod Pathol* 2012;25: 1181-92.
- [11] Yamamoto M, Takahashi H, Tabeya T, et al. Risk of malignancies in IgG4-related disease. *Mod Rheumatol* 2012;22:414-8.
- [12] Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. *Nat Med* 1998;4:844-7.
- [13] Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. *Pathology and genetics of tumours of the lung, pleura, thymus and heart*. Lyon: IARC Press; 2004.
- [14] Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol* 2011; 6:244-85.
- [15] Sonobe M, Manabe T, Wada H, Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. *Br J Cancer* 2005;93:355-63.
- [16] Sonobe M, Kobayashi M, Ishikawa M, et al. Impact of *KRAS* and *EGFR* gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas. *Ann Surg Oncol* 2012; 19(Suppl 3):S347-54.

- [17] Sobin LH, Gospodarowicz MK, Wittekind CH, editors. TNM classification of malignant tumors. 7th ed. Oxford: Wiley-Blackwell; 2009. p. 138-46.
- [18] O'Callaghan DS, O'Donnell D, O'Connell F, O'Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. *J Thorac Oncol* 2010;5:2024-36.
- [19] Yamashita K, Haga H, Kobashi Y, Miyagawa-Hayashino A, Yoshizawa A, Manabe T. Lung involvement in IgG4-related lymphoplasmacytic vasculitis and interstitial fibrosis: report of 3 cases and review of the literature. *Am J Surg Pathol* 2008;32:1620-6.
- [20] Burks AW, Jones SM, Wood RA, et al. Oral immunotherapy for treatment of egg allergy in children. *N Engl J Med* 2012;367:233-43.
- [21] Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheifflinger F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. *J Thromb Haemost* 2009;7:1703-10.
- [22] Sitaru C, Mihai S, Zillikens D. The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases. *Arch Dermatol Res* 2007;299:1-8.
- [23] Debiec H, Lefeu F, Kemper MJ, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. *N Engl J Med* 2011;364:2101-10.
- [24] Beck Jr LH, Salant DJ. Membranous nephropathy: recent travels and new roads ahead. *Kidney Int* 2010;77:765-70.
- [25] Holland M, Hewins P, Goodall M, Adu D, Jefferis R, Savage CO. Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass. *Clin Exp Immunol* 2004;138:183-92.
- [26] Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. *Mod Pathol* 2011;24:653-64.